Chicago orthopedic surgeon, Mitchell Sheinkop, M.D., in collaboration with Regenerative Sciences, Inc., is seeking qualified candidates in Illinois, Wisconsin, Indiana, and Michigan for a clinical trial comparing the efficacy of stem cell therapy to traditional treatments for degenerative knee conditions. Regenerative Sciences, Inc. is a Colorado-based company that specializes in regenerative orthopedic medicine. Sheinkop is a board certified orthopedic surgeon, former director of the joint replacement program and professor emeritus at Rush University Medical Center.
Subjects Needed For Stem Cell Trial
1 min read Premium comments
Secondary
Knee osteoarthritis is one of the most common degenerative joint conditions in the United States, affecting millions of individuals and resulting in 700, 000 knee replacements a year, according to the release by Rosner Public Relations. In the study the Regenexx stem cell therapy will be compared and measured against the treatments given to a control group of patients undergoing exercise therapy and other non-surgical modalities, as well as historical results of those who have had knee replacement surgery.
The study will focus on patients, 18 to 70 years old with injuries, arthritis and other degenerative conditions of the knee. Those who qualify will receive the treatment at no cost to the patient, but they must agree to a periodic assessment protocol over a two year period.
“Regenerative Sciences continues to be at the forefront of regenerative orthopedic medicine in the United States and Europe. I have seen the ability of these new biological treatments help heal injuries and degenerative conditions without surgery and I believe they will soon become the new-normal for treating many orthopedic conditions, ” said Sheinkop.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.